PPT-Pharmacovigilance and drug safety trainings to increase Tuberculosis (TB) preventive treatment

Authors 1 Juliet Jokwiro 1 Nicole ChekudambuneKawaza 1 Kenny Sithole 1 Bongani Dube 2 Charles Sandy 2 Manners Ncube 2 Regina Mubau 2 Chlorata Gwanzura 2 Kwenziweyinkosi Ndlovu . New challenges for WHO. Dr Shanthi Pal. . Group Lead, Medicines Safety . . Director/EMP . K. De . Joncheere. Coordinator PAU. G. Forte. Head/RHT. L.Rago. Coordinator/PHI. M Zafar. Coordinator /PQT. Why do we test?. 1. We want to prevent an outbreak of Tuberculosis in our campus community. 2. We want to find those that are affected and get them treated so you are able to continue to participate in your schooling. . New challenges for WHO. Dr Shanthi Pal. . Group Lead, Medicines Safety . . Director/EMP . K. De . Joncheere. Coordinator PAU. G. Forte. Head/RHT. L.Rago. Coordinator/PHI. M Zafar. Coordinator /PQT. JAMASOFT2017. 1. Social. Pharmacy. Pharmacoepidemiology. Pharmacovigilance. JAMASOFT2017. 2. P. armacovigilance. system collects data . throughout the . lifecycle . of each . medicinal. . product. , MD. Pfizer, India. DISCLAIMER. Overview. Introduction & Terminology. Why Pharmacovigilance?. Pharmacovigilance Practices. : International & Indian. PVPI. Drug Safety Issues in Clinical Trials . Shanthi Pal. Leader, Medicines Safety. Safety . and Vigilance,. WHO, Geneva. What is pharmacovigilance. The science and activities relating to the detection, assessment, understanding and prevention of . Akujobi. CN, . Okoro. CE, . Anyabolu. AE, . Okonkwo. RC, . Onwunzo. MC and . Chukwuka. CP. Tuberculosis (TB) is the most common opportunistic infection in Human . Immuno. d. eficiency . Virus (HIV. Dr Shanthi Pal. . Group Lead, Medicines Safety . . Director/EMP . K. De . Joncheere. Coordinator PAU. G. Forte. Head/RHT. L.Rago. Coordinator/PHI. M Zafar. Coordinator /PQT. Coordinator RSS. N Dellepiane. Shanthi Pal. Leader, Medicines Safety. Safety . and Vigilance,. WHO, Geneva. What is pharmacovigilance. The science and activities relating to the detection, assessment, understanding and prevention of . Mrs.Indumathi. Lecturer . YNC. OBJECTIVE. By the end of the session the student will be able to:. define tuberculosis. explain the epidemiological triad of tuberculosis. identify the mode of transmission and incubation period. Strength of the recommendationAPreferred should generally be offeredBAlternative acceptable to offerCOffer when preferred or alternative regimens cannot be givenDShould generally not be offeredEShould 1466 Nikhil GuptaKavita BahmaniAjit Jangra IntroductionPharmacovigilance and drug safety remains As per the World Health Organization (WHO), Pharmacovigilance may be dened ClinicalPractice ISSN The treatment of drug-susceptible. and drug-resistant tuberculosis. Antwerp, 11 April 2019. Hans L Rieder. Efficacy, effectiveness, efficiency…. Efficacy. What can the drug do? (ideal conditions, simulated in clinical trial settings: factually evaluating . Malik AA, Gandhi NR, Lash TL, Cranmer LM, Omer SB, Ahmed JF, et al. Effectiveness of Preventive Therapy for Persons Exposed at Home to Drug-Resistant Tuberculosis, Karachi, Pakistan. Emerg Infect Dis. 2021;27(3):805-812. https://doi.org/10.3201/eid2703.203916.